Clinical Research Division, Fred Hutch
Medical Director, Adult Blood and Marrow Transplantation
Dr. Marco Mielcarek is the medical director of the Adult Blood and Marrow Transplant Program at Fred Hutchinson Cancer Center. His research focuses on graft-vs.-host disease, or GVHD, a potentially life-threatening complication in which newly transplanted cells attack the patient’s body. Dr. Mielcarek and his research colleagues are testing in clinical trials how to better prevent GVHD and how to effectively treat it without causing unwanted toxicity. He and his colleagues have shown that carefully timed infusions of high doses of cyclophosphamide, a common chemotherapy drug, can safely and effectively prevent GVHD after growth factor-mobilized blood stem transplantation.
University of Washington School of Medicine
Medical Oncology Fellowship, University of Washington, 2000-2003
Internal Medicine Residency, University of Washington, 1998-2000
Internal Medicine Residency, Freie Universität Berlin, 1987-1993
Ph.D., Freie Universität Berlin, School of Medicine, 1987
M.D., Freie Universität Berlin, School of Medicine, Germany, 1986
Preventing and more effectively treating graft-versus-host disease (GVHD) after allogeneic stem cell transplantation.
The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.
Email email@example.com or call 206.667.2210